PL2605771T3 - Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych - Google Patents

Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych

Info

Publication number
PL2605771T3
PL2605771T3 PL11751717T PL11751717T PL2605771T3 PL 2605771 T3 PL2605771 T3 PL 2605771T3 PL 11751717 T PL11751717 T PL 11751717T PL 11751717 T PL11751717 T PL 11751717T PL 2605771 T3 PL2605771 T3 PL 2605771T3
Authority
PL
Poland
Prior art keywords
alpha
cells
receptor agonists
adrenergic receptor
activating regulatory
Prior art date
Application number
PL11751717T
Other languages
English (en)
Inventor
Daniel W. Gil
John E. Donello
Lauren M.B. Luhrs
Veena Viswanath
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL2605771T3 publication Critical patent/PL2605771T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11751717T 2010-08-16 2011-08-11 Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych PL2605771T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37412410P 2010-08-16 2010-08-16
PCT/US2011/047426 WO2012024161A1 (en) 2010-08-16 2011-08-11 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
EP11751717.7A EP2605771B1 (en) 2010-08-16 2011-08-11 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
PL2605771T3 true PL2605771T3 (pl) 2018-10-31

Family

ID=44543836

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751717T PL2605771T3 (pl) 2010-08-16 2011-08-11 Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych

Country Status (18)

Country Link
US (5) US8575207B2 (pl)
EP (2) EP2605771B1 (pl)
JP (3) JP5938407B2 (pl)
KR (3) KR102013086B1 (pl)
CN (3) CN103153296B (pl)
AU (1) AU2011292296B2 (pl)
BR (1) BR112013003590A2 (pl)
CA (1) CA2808307C (pl)
DK (1) DK2605771T3 (pl)
ES (1) ES2676194T3 (pl)
HK (1) HK1256823A1 (pl)
HU (1) HUE038366T2 (pl)
PL (1) PL2605771T3 (pl)
PT (1) PT2605771T (pl)
RU (2) RU2599495C2 (pl)
SI (1) SI2605771T1 (pl)
TR (1) TR201809456T4 (pl)
WO (1) WO2012024161A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276648A1 (en) * 2009-07-30 2012-02-23 Allergan, Inc. Selective alpha 2B/2C agonists
PL2605771T3 (pl) 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
US20150313896A1 (en) * 2013-07-26 2015-11-05 Galderma Research & Development Method for treating cell proliferation disorders
MX2017010544A (es) * 2015-02-24 2018-06-18 Univ Illinois Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US20180250369A1 (en) * 2015-09-11 2018-09-06 Ventria Bioscience, Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
CN108367163A (zh) * 2015-10-05 2018-08-03 黄静峰 用于治疗干眼及相关眼表疾病的治疗性组合物
BR112018071559B1 (pt) * 2016-04-22 2024-02-06 Viking Therapeutics, Inc Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x
WO2018212846A1 (en) 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
US20250124501A1 (en) * 2023-10-12 2025-04-17 Kyung Mi Kim System and method for client-server model including ai-enable processing for financial products

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2835423A1 (de) 1978-08-12 1980-03-06 Hoechst Ag Beton- und moertelzusatzmittel und dessen verwendung
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
WO2005034998A2 (en) 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006036480A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
CA2582071A1 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
CA2672617A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2-imidazoles as ligands for trace amine associated receptors (taar)
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
MX2010001351A (es) 2007-08-03 2010-06-25 Mill Steel Co Aparato para determinar el perfil de calibre para material enrollado plano.
WO2009020578A1 (en) * 2007-08-06 2009-02-12 Schering Corporation Alpha2c adrenoreceptor agonists
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US8735399B2 (en) 2008-01-18 2014-05-27 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US8809379B2 (en) * 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
ES2672777T3 (es) * 2008-06-09 2018-06-18 Allergan, Inc. Métodos de tratamiento de estados con mediación alfa-adrenérgica
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US8063231B2 (en) 2008-06-09 2011-11-22 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
AU2010276648A1 (en) 2009-07-30 2012-02-23 Allergan, Inc. Selective alpha 2B/2C agonists
PL2605771T3 (pl) 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych

Also Published As

Publication number Publication date
AU2011292296B2 (en) 2015-09-03
KR102013086B1 (ko) 2019-08-21
US9545394B2 (en) 2017-01-17
HUE038366T2 (hu) 2018-10-29
JP2016117781A (ja) 2016-06-30
CN114073696A (zh) 2022-02-22
BR112013003590A2 (pt) 2016-05-31
CN103153296A (zh) 2013-06-12
JP2013534246A (ja) 2013-09-02
PT2605771T (pt) 2018-07-09
CA2808307A1 (en) 2012-02-23
RU2016134989A (ru) 2018-12-11
CN108272797B (zh) 2021-04-27
JP6509307B2 (ja) 2019-05-08
RU2013110877A (ru) 2014-09-27
JP2018027984A (ja) 2018-02-22
JP6250728B2 (ja) 2017-12-20
ES2676194T3 (es) 2018-07-17
US20160158199A1 (en) 2016-06-09
TR201809456T4 (tr) 2018-07-23
CN103153296B (zh) 2018-02-13
US8575207B2 (en) 2013-11-05
US10251865B2 (en) 2019-04-09
RU2599495C2 (ru) 2016-10-10
EP3332782A1 (en) 2018-06-13
CN108272797A (zh) 2018-07-13
HK1258043A1 (zh) 2019-11-01
US20180071259A1 (en) 2018-03-15
AU2011292296A1 (en) 2013-03-14
WO2012024161A1 (en) 2012-02-23
JP5938407B2 (ja) 2016-06-22
CA2808307C (en) 2022-06-21
US20140066483A1 (en) 2014-03-06
KR20180040710A (ko) 2018-04-20
KR101847669B1 (ko) 2018-05-24
US20120041031A1 (en) 2012-02-16
DK2605771T3 (en) 2018-07-16
HK1256823A1 (en) 2019-10-04
US9289420B2 (en) 2016-03-22
US20170079956A1 (en) 2017-03-23
EP2605771B1 (en) 2018-04-04
KR20130108301A (ko) 2013-10-02
KR20190097323A (ko) 2019-08-20
RU2016134989A3 (pl) 2020-02-17
EP2605771A1 (en) 2013-06-26
SI2605771T1 (sl) 2018-09-28

Similar Documents

Publication Publication Date Title
PL2605771T3 (pl) Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
ZA201300621B (en) T cell receptors
IL254469A0 (en) Anti–2–ssx t cell receptors and related substances and methods of use
EP2719010A4 (en) MATERIALS FOR BATTERY ELECTROLYTE AND METHOD FOR THEIR USE
IL245440A0 (en) A method for activating a t-helper cell
PT3527584T (pt) Recetores de célula t anti-ny-eso-1 murinos
SI2683815T1 (sl) Gensko modificirana celica in postopek za uporabo omenjene celice
IL228740A0 (en) fgfri agonists and methods of use
EP2585951A4 (en) PERSONAL ASSISTANT FOR THE USE OF TASKS
PL2526581T3 (pl) Materiały kompozytowe do magazynowania elektrochemicznego
GB0911566D0 (en) T cell receptors
IL227185B (en) A method for growing animal cells
EP2709128A4 (en) ELECTROCHEMICAL CELL
PL2649068T3 (pl) Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX
EP2551380A4 (en) ELECTROCHEMICAL DEVICE
GB201118641D0 (en) Electrochemical cell
GB201121170D0 (en) Galvanic cells and components therefore
EP2579361A4 (en) DEVICE FOR PROVIDING AN ELECTROLYTIC SOLUTION
IL230767A0 (en) A clean translation system is suitable for sorting compounds and related uses
GB2495717B (en) Gangway for an offshore structure
GB2481541B (en) Electrochemical test devices
EP2554659A4 (en) PROCESS FOR PREPARING ES CELLS
GB201009136D0 (en) Electrochemical method
IL223436A (en) Methods for preparing tetranor - pgdm and tetranor - pgjm
TWM401779U (en) Positioning structure of testing machine